Blind scoring depicted that both AD-MSCs and apelin ameliorated ischemic damage and ambulatory impairment compared with that of PBS group (Fig. 2C,D), while combined therapy of AD-MSCs and apelin further improved functional recovery of ischemic hindlimbs (Fig. 2C,D). Here, APLN is linked to Alzheimer disease.